Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study.

Miwa K

Open source

DOI
10.1016/j.ensci.2024.100537
Published
2025 Mar
Container
eNeurologicalSci
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ensci.2024.100537,
  title = {Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study.},
  author = {Miwa K},
  year = {2025},
  journal = {eNeurologicalSci},
  doi = {10.1016/j.ensci.2024.100537},
  url = {https://doi.org/10.1016/j.ensci.2024.100537}
}

RIS

TY  - JOUR
TI  - Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study.
AU  - Miwa K
PY  - 2025
JO  - eNeurologicalSci
DO  - 10.1016/j.ensci.2024.100537
UR  - https://doi.org/10.1016/j.ensci.2024.100537
ER  - 

APA

K, M. (2025). Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study.. eNeurologicalSci. https://doi.org/10.1016/j.ensci.2024.100537

Source records